MA32982B1 - Proteines de liaison au recepteur cgrp humain - Google Patents

Proteines de liaison au recepteur cgrp humain

Info

Publication number
MA32982B1
MA32982B1 MA34035A MA34035A MA32982B1 MA 32982 B1 MA32982 B1 MA 32982B1 MA 34035 A MA34035 A MA 34035A MA 34035 A MA34035 A MA 34035A MA 32982 B1 MA32982 B1 MA 32982B1
Authority
MA
Morocco
Prior art keywords
binding proteins
cgrp
human cgrp
cgrp receptors
antigen
Prior art date
Application number
MA34035A
Other languages
Arabic (ar)
English (en)
Inventor
Thomas C Boone
David W Brankow
Jr Colin V Gegg
Shaw-Fen Sylvia Hu
Chadwick T King
Hsieng Sen Lu
Licheng Shi
Cen Xu
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA32982B1 publication Critical patent/MA32982B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)

Abstract

L'invention porte sur des protéines de liaison à un antigène qui se lient au récepteur CGRP humain (CGRP R). L'invention porte également sur des acides nucléiques codant pour la protéine de liaison à un antigène, sur des vecteurs et des cellules codant pour ceux-ci. Les protéines de liaison à un antigène peuvent inhiber la liaison de CGRP R à CGRP, et sont utiles dans un nombre de troubles liés à CGRP R, comprenant le traitement et/ou la prévention de maux de tête migraineux.
MA34035A 2008-12-23 2009-12-18 Proteines de liaison au recepteur cgrp humain MA32982B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20356908P 2008-12-23 2008-12-23
US26462209P 2009-11-25 2009-11-25
PCT/US2009/068858 WO2010075238A1 (fr) 2008-12-23 2009-12-18 Protéines de liaison au récepteur cgrp humain

Publications (1)

Publication Number Publication Date
MA32982B1 true MA32982B1 (fr) 2012-01-02

Family

ID=41718325

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34035A MA32982B1 (fr) 2008-12-23 2009-12-18 Proteines de liaison au recepteur cgrp humain

Country Status (42)

Country Link
US (7) US9102731B2 (fr)
EP (4) EP3569620B1 (fr)
JP (6) JP5761805B2 (fr)
KR (4) KR20180043850A (fr)
CN (2) CN102348722B (fr)
AR (1) AR074857A1 (fr)
AU (2) AU2009330175C1 (fr)
BR (2) BRPI0922505B1 (fr)
CA (1) CA2746858C (fr)
CL (1) CL2011001578A1 (fr)
CO (1) CO6400232A2 (fr)
CR (1) CR20110400A (fr)
CY (3) CY1119465T1 (fr)
DK (3) DK3184546T3 (fr)
EA (2) EA031320B1 (fr)
ES (3) ES3036151T3 (fr)
FI (1) FI3569620T3 (fr)
HR (3) HRP20250807T8 (fr)
HU (4) HUE072123T2 (fr)
IL (2) IL213429A (fr)
JO (2) JO3382B1 (fr)
LT (4) LT3569620T (fr)
LU (1) LUC00095I2 (fr)
MA (1) MA32982B1 (fr)
ME (1) ME03601B (fr)
MX (1) MX2011006804A (fr)
MY (1) MY180564A (fr)
NL (1) NL300961I2 (fr)
NO (2) NO2379594T3 (fr)
NZ (2) NZ623541A (fr)
PE (1) PE20120427A1 (fr)
PL (3) PL2379594T3 (fr)
PT (3) PT3184546T (fr)
RS (3) RS56567B1 (fr)
SG (2) SG172307A1 (fr)
SI (3) SI2379594T1 (fr)
SM (1) SMT201700504T1 (fr)
TN (1) TN2011000283A1 (fr)
TW (4) TWI574697B (fr)
UA (1) UA108066C2 (fr)
WO (1) WO2010075238A1 (fr)
ZA (1) ZA201105418B (fr)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3045182T1 (en) 2005-11-14 2018-08-31 Teva Pharmaceuticals International Gmbh An antibody to a peptide-associated peptide antagonist to calcitonin for treating a headache in aggregates
CN101925611A (zh) * 2007-11-21 2010-12-22 安姆根有限公司 Wise结合剂和表位
EP2265287B1 (fr) 2008-03-04 2018-09-05 Teva Pharmaceuticals International GmbH Procédés de traitement d'une douleur chronique
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
WO2011024113A1 (fr) 2009-08-28 2011-03-03 Rinat Neuroscience Corporation Procédés de traitement de la douleur viscérale par administration d'anticorps antagonistes dirigés contre le peptide associé au gène de la calcitonine
CA3048709C (fr) * 2011-05-20 2026-02-24 H. Lundbeck A/S. Utilisation d'anticorps et de fragments d'anticorps anti-cgrp dans la prevention ou l'inhibition de la photophobie ou de l'aversion a la lumiere chez des sujets qui en ont besoin,en particulier des personnes souffrant de migraines
TWI692485B (zh) 2011-05-20 2020-05-01 美商艾爾德生物控股有限責任公司 抗降血鈣素基因相關胜肽（ａｎｔｉ-ｃｇｒｐ）組成物及其用途
CA2836799C (fr) 2011-05-20 2021-05-18 Alderbio Holdings Llc Utilisation d'anticorps ou de fragments d'anticorps anti-cgrp ou anti-cgrp-r dans le traitement ou la prevention de formes chroniques et aigues de la diarrhee
SG11201507416WA (en) * 2013-03-15 2015-10-29 Amgen Inc Human pac1 antibodies
AU2014236867A1 (en) 2013-03-15 2015-09-24 Amgen Inc. Methods and compositions relating to anti-CCR7 antigen binding proteins
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
TWI805996B (zh) 2013-08-05 2023-06-21 美商扭轉生物科技有限公司 重新合成之基因庫
EP3060275B1 (fr) 2013-10-24 2019-07-03 Amgen Inc. Injecteur et procédé d'assemblage
AU2014340174B2 (en) 2013-10-24 2019-09-12 Amgen Inc. Drug delivery system with temperature-sensitive control
WO2015119906A1 (fr) 2014-02-05 2015-08-13 Amgen Inc. Système d'administration de médicament doté d'un générateur de champ électromagnétique
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
HUE065397T2 (hu) 2014-03-21 2024-06-28 Teva Pharmaceuticals Int Gmbh Kalcitonin génekkel kapcsolatos peptid elleni antagonista antitestek és azokat alkalmazó eljárások
EP3785749B1 (fr) 2014-05-07 2026-04-01 Amgen Inc. Auto-injecteur doté d'éléments de réduction de choc
EP4036924A1 (fr) 2014-06-03 2022-08-03 Amgen, Inc Dispositifs et procédés destinés à aider un utilisateur d'un dispositif d'administration de médicaments
AU2015318008B2 (en) * 2014-09-15 2021-05-20 Amgen Inc. Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof
WO2016061220A2 (fr) 2014-10-14 2016-04-21 Amgen Inc. Dispositif d'injection de médicament comportant des témoins visuels et sonores
US10799630B2 (en) 2014-12-19 2020-10-13 Amgen Inc. Drug delivery device with proximity sensor
EP3689394A1 (fr) 2014-12-19 2020-08-05 Amgen Inc. Dispositif d'administration de médicaments avec bouton mobile ou panneau d'interface utilisateur
US20160208018A1 (en) 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1
WO2016126882A1 (fr) 2015-02-04 2016-08-11 Twist Bioscience Corporation Procédés et dispositifs pour assemblage de novo d'acide oligonucléique
WO2016133947A1 (fr) 2015-02-17 2016-08-25 Amgen Inc. Dispositif d'administration de médicament à sécurisation assistée par dépression et/ou retour d'informations
EP3981450A1 (fr) 2015-02-27 2022-04-13 Amgen, Inc Dispositif d'administration de médicament ayant un mécanisme de protection d'aiguille présentant un seuil réglable de résistance au mouvement de l'élément de protection d'aiguille
US9981239B2 (en) 2015-04-21 2018-05-29 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
TWI799849B (zh) 2015-04-24 2023-04-21 美商安美基公司 治療或預防偏頭痛之方法
US10464983B2 (en) 2015-05-13 2019-11-05 The Board Of Regents Of The University Of Oklahoma Variants of adrenomedullin and calcitonin gene-related peptide and methods of use
WO2017039786A1 (fr) 2015-09-02 2017-03-09 Amgen Inc. Adaptateur d'ensemble de seringue pour une seringue
HK1258869A1 (zh) 2015-09-18 2019-11-22 Twist Bioscience Corporation 寡核酸变体文库及其合成
CN108698012A (zh) 2015-09-22 2018-10-23 特韦斯特生物科学公司 用于核酸合成的柔性基底
US11351308B2 (en) 2015-12-09 2022-06-07 Amgen Inc. Auto-injector with signaling cap
WO2017120178A1 (fr) 2016-01-06 2017-07-13 Amgen Inc. Auto-injecteur pourvu d'une électronique de signalisation
MX2018009011A (es) 2016-02-02 2018-11-19 Hutchinson Fred Cancer Res Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos.
EP3721922B1 (fr) 2016-03-15 2022-05-04 Amgen Inc. Réduction de la probabilité de rupture de verre dans des dispositifs d'administration de médicament
CN109311977B (zh) 2016-04-15 2022-06-14 H.伦德贝克公司 人源化的抗pacap抗体及其用途
US11541168B2 (en) 2016-04-29 2023-01-03 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
AU2017263558B2 (en) 2016-05-13 2022-12-22 Amgen Inc. Vial sleeve assembly
US11238150B2 (en) 2016-05-16 2022-02-01 Amgen Inc. Data encryption in medical devices with limited computational capability
US11541176B2 (en) 2016-06-03 2023-01-03 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
US11285266B2 (en) 2016-07-01 2022-03-29 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
EP3516528B1 (fr) 2016-09-21 2025-10-15 Atlas Data Storage, Inc. Stockage de données reposant sur un acide nucléique
WO2018055574A1 (fr) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Traitement de la migraine réfractaire
AU2017331592A1 (en) 2016-09-23 2019-04-11 Teva Pharmaceuticals International Gmbh Treating cluster headache
WO2018081234A1 (fr) 2016-10-25 2018-05-03 Amgen Inc. Injecteur porté sur le corps
US11993645B2 (en) 2017-01-11 2024-05-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions comprising R-Spondin (RSPO) surrogate molecules
CA3049780A1 (fr) 2017-01-17 2018-07-26 Amgen Inc. Dispositifs d'injection et procedes d'utilisation et d'assemblage associes
WO2018140821A1 (fr) 2017-01-26 2018-08-02 Surrozen, Inc. Molécules d'amélioration de signal wnt spécifiques au tissu et leurs utilisations
JP7280189B2 (ja) 2017-02-17 2023-05-23 アムジエン・インコーポレーテツド 薬物送達装置用の挿入機構
EP3582825A1 (fr) 2017-02-17 2019-12-25 Amgen Inc. Dispositif d'administration de médicament à trajet d'écoulement de fluide stérile et procédé d'assemblage associé
KR20240158370A (ko) 2017-02-22 2024-11-04 트위스트 바이오사이언스 코포레이션 핵산 기반 데이터 저장
CA3055195A1 (fr) 2017-03-02 2018-09-07 Beth Israel Deaconess Medical Center, Inc. Selection de patients atteints de cephalees presentant une reponse a des anticorps diriges contre un peptide lie au gene de la calcitonine
MX2019010544A (es) 2017-03-06 2019-10-21 Amgen Inc Dispositivo de administracion de farmacos con caracteristica de prevencion de la activacion.
KR102627069B1 (ko) 2017-03-07 2024-01-18 암겐 인코포레이티드 과압에 의한 바늘 삽입
KR102893480B1 (ko) 2017-03-09 2025-11-28 암겐 인코포레이티드 약물 전달 장치용 삽입 메커니즘
BR112019020053B1 (pt) 2017-03-28 2023-10-10 Amgen Inc Máquina para acoplar uma haste de êmbolo a um conjunto de seringa e método de utilização da referida máquina
MX2019014615A (es) 2017-06-08 2020-02-07 Amgen Inc Dispositivo de administracion de farmacos accionado por par de torsion.
WO2018226515A1 (fr) 2017-06-08 2018-12-13 Amgen Inc. Ensemble de seringue d'un appareil d'administration de médicament et procédé d'assemblage
AU2018288604B2 (en) 2017-06-22 2023-12-21 Amgen Inc. Device activation impact/shock reduction
AU2018290302B2 (en) 2017-06-23 2024-02-29 Amgen Inc. Electronic drug delivery device comprising a cap activated by a switch assembly
MA49562A (fr) 2017-07-14 2020-05-20 Amgen Inc Système d'insertion-rétractation d'aiguille présentant un système à ressort en double torsion
EP4292576A3 (fr) 2017-07-21 2024-01-17 Amgen Inc. Élément d'étanchéité perméable aux gaz pour récipient de médicament et procédés d'assemblage
WO2019022951A1 (fr) 2017-07-25 2019-01-31 Amgen Inc. Dispositif d'administration de médicament avec module d'engrenage et procédé d'assemblage associé
WO2019022950A1 (fr) 2017-07-25 2019-01-31 Amgen Inc. Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé
EP3664863A2 (fr) 2017-08-09 2020-06-17 Amgen Inc. Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre
US11077246B2 (en) 2017-08-18 2021-08-03 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
ES2939292T3 (es) 2017-10-04 2023-04-20 Amgen Inc Adaptador de flujo para dispositivo de administración de fármacos
EP4257164A3 (fr) 2017-10-06 2024-01-17 Amgen Inc. Dispositif d'administration de médicament comprenant un ensemble de verrouillage et procédé d'assemblage associé
MA50348A (fr) 2017-10-09 2020-08-19 Amgen Inc Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé
US10894242B2 (en) 2017-10-20 2021-01-19 Twist Bioscience Corporation Heated nanowells for polynucleotide synthesis
EP3703779B1 (fr) 2017-11-03 2026-01-28 Amgen Inc. Systemes et approches pour la sterilisation d'un dispositif d'administration de medicaments
US12053618B2 (en) 2017-11-06 2024-08-06 Amgen Inc. Fill-finish assemblies and related methods
MA50553A (fr) 2017-11-06 2020-09-16 Amgen Inc Dispositif d'administration de médicament avec détection de positionnement et de débit
IL273637B2 (en) 2017-11-10 2025-09-01 Amgen Inc Pistons for drug delivery devices
AU2018368340B2 (en) 2017-11-16 2024-03-07 Amgen Inc. Door latch mechanism for drug delivery device
AU2019207915B2 (en) 2018-01-12 2025-09-04 Amgen Inc. PAC1 antibodies and uses thereof
EA202092335A1 (ru) 2018-04-02 2021-01-22 Эмджен Инк. Композиции на основе эренумаба и пути их применения
KR102791798B1 (ko) 2018-04-12 2025-04-07 암젠 인크 안정한 단백질 조성물의 제조 방법
SG11202011467RA (en) 2018-05-18 2020-12-30 Twist Bioscience Corp Polynucleotides, reagents, and methods for nucleic acid hybridization
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
JP2021530223A (ja) 2018-07-09 2021-11-11 スロゼン， インコーポレイテッド 組織特異性Ｗｎｔシグナル増強分子及びその使用
WO2020023336A1 (fr) 2018-07-24 2020-01-30 Amgen Inc. Dispositifs hybrides d'administration de médicament dotés d'une partie de préhension
WO2020023444A1 (fr) 2018-07-24 2020-01-30 Amgen Inc. Dispositifs d'administration pour l'administration de médicaments
WO2020023220A1 (fr) 2018-07-24 2020-01-30 Amgen Inc. Dispositifs d'administration de médicament hybrides dotés d'une partie de fixation collante à placer sur la peau et procédé de préparation associé
WO2020023451A1 (fr) 2018-07-24 2020-01-30 Amgen Inc. Dispositifs d'administration pour l'administration de médicaments
CA3103105A1 (fr) 2018-07-31 2020-02-06 Amgen Inc. Ensemble de trajet de fluide pour dispositif d'administration de medicament
JP2022500095A (ja) 2018-09-24 2022-01-04 アムジエン・インコーポレーテツド インターベンション投薬システム及び方法
IL281469B2 (en) 2018-09-28 2024-08-01 Amgen Inc Muscle wire escapement activation assembly for a drug delivery device
MA53815A (fr) 2018-10-02 2022-01-05 Amgen Inc Systèmes d'injection pour administration de médicament avec transmission de force interne
AU2019355979B2 (en) 2018-10-05 2024-12-05 Amgen Inc. Drug delivery device having dose indicator
TWI846741B (zh) 2018-10-15 2024-07-01 美商安進公司 用於藥物遞送裝置之平台組裝方法
JP7719714B2 (ja) 2018-10-15 2025-08-06 アムジエン・インコーポレーテツド ダンピング機構を有する薬物送達装置
CA3113076A1 (fr) 2018-11-01 2020-05-07 Amgen Inc. Dispositifs d'administration de medicament a retraction partielle d'element d'administration de medicament
ES3010833T3 (en) 2018-11-01 2025-04-04 Amgen Inc Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
CN113692409B (zh) 2018-12-26 2025-01-10 特韦斯特生物科学公司 高度准确的从头多核苷酸合成
JOP20210156A1 (ar) 2019-01-08 2023-01-30 H Lundbeck As علاج إسعافي وعلاج سريع للصداع باستخدام أجسام مضادة لـ cgrp
US11492728B2 (en) 2019-02-26 2022-11-08 Twist Bioscience Corporation Variant nucleic acid libraries for antibody optimization
EP3930753A4 (fr) * 2019-02-26 2023-03-29 Twist Bioscience Corporation Banques de variants d'acides nucléiques pour le récepteur glp1
JP7510952B2 (ja) 2019-04-24 2024-07-04 アムジエン・インコーポレーテツド シリンジ滅菌確認アセンブリ及び方法
CN114127110B (zh) * 2019-05-30 2022-07-01 山东博安生物技术股份有限公司 抗cgrp抗体及其应用
AU2020304671A1 (en) 2019-06-28 2022-01-20 Amgen Inc. Anti-CGRP receptor/anti-PAC1 receptor bispecific antigen binding proteins
CA3148261A1 (fr) 2019-08-23 2021-03-04 Amgen Inc. Dispositif d'administration de medicament dote de composants configurables de mise en prise de protection d'aiguille et methodes associees
CN115023440B (zh) 2019-09-23 2025-09-12 特韦斯特生物科学公司 结合CD3ε的抗体
EP4464827A3 (fr) 2019-09-23 2025-02-26 Twist Bioscience Corporation Banques d'acides nucléiques variants pour crth2
KR20210124867A (ko) 2020-04-06 2021-10-15 하. 룬드벡 아크티에셀스카브 항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료
WO2022104280A1 (fr) 2020-11-16 2022-05-19 Surrozen Operating, Inc. Molécules d'amélioration de signaux wnt spécifiques du fois et leurs utilisations
EP4301362A1 (fr) 2021-03-02 2024-01-10 CGRP Diagnostics GmbH Traitement et/ou réduction de l'apparition de migraine
US20240208680A1 (en) 2021-05-21 2024-06-27 Amgen Inc. Method of optimizing a filling recipe for a drug container
US20250109188A1 (en) 2021-08-24 2025-04-03 Cgrp Diagnostics Gmbh Preventative treatment of migraine
JP2025515038A (ja) * 2022-05-05 2025-05-13 アムジェン インコーポレイテッド Ｄｌｌ３及びｃｄ３に結合するヘテロ多量体
TW202432600A (zh) 2022-11-07 2024-08-16 美商安進公司 用於治療肥胖症之方法
WO2025226754A1 (fr) 2024-04-23 2025-10-30 Amgen Inc. Procédé de prédiction de l'osmolalité de solutions protéiques
CN118459595A (zh) * 2024-05-21 2024-08-09 杭州百懿生物药业有限公司 特异性结合cgrp受体的抗体分子及其用途
WO2026030152A1 (fr) 2024-07-29 2026-02-05 Amgen Inc. Système et procédé d'évaluation de la transférabilité d'une recette de remplissage

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
EP0281604B1 (fr) 1986-09-02 1993-03-31 Enzon Labs Inc. Molecules de liaison de chaines de polypeptide simples
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (fr) 1988-10-31 1990-05-17 Immunex Corporation Recepteurs d'interleukine-4
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JPH02229119A (ja) 1989-02-28 1990-09-11 Toyo Jozo Co Ltd 動脈硬化予防および治療剤
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
WO1991018982A1 (fr) 1990-06-05 1991-12-12 Immunex Corporation Recepteurs de l'interleukine-1 de type ii
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
JP3126980B2 (ja) 1991-03-11 2001-01-22 ザ・ユニバーシテイ・オブ・ジヨージア・リサーチ・フアウンデーシヨン・インコーポレーテツド レニラ（ｒｅｎｉｌｌａ）ルシフェラーゼのクローニング及び発現
JPH06508035A (ja) 1991-06-14 1994-09-14 ディーエヌエックス　コーポレーション トランスジェニックブタにおけるヒトヘモグロビンの生産
WO1993001227A1 (fr) 1991-07-08 1993-01-21 University Of Massachusetts At Amherst Copolymere en masse segmentee a cristaux liquides thermotropiques
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
AU673347B2 (en) * 1992-03-17 1996-11-07 Novartis Ag Genetically engineered antibodies
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
ATE240394T1 (de) 1992-10-23 2003-05-15 Immunex Corp Methoden zur herstellung löslicher, oligomerer proteine
US5766880A (en) * 1992-10-27 1998-06-16 Queen's University At Kingston Isolated nucleic acid molecules encoding multidrug resistance proteins
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
AU694745B2 (en) 1993-09-10 1998-07-30 Trustees Of Columbia University In The City Of New York, The Uses of green fluorescent protein
WO1995021191A1 (fr) 1994-02-04 1995-08-10 William Ward Indicateur bioluminescent fonde sur l'expression d'un gene codant pour une proteine modifiee a fluorescence verte
WO1996003993A2 (fr) 1994-08-05 1996-02-15 The Rockefeller University Modulation de l'activite fonctionnelle de thymocytes et de lymphocytes t
AU7953194A (en) 1994-08-16 1996-03-07 Human Genome Sciences, Inc. Calcitonin receptor
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
AU6596096A (en) 1996-07-23 1998-02-10 Smithkline Beecham Corporation Calcitonin gene-related peptide receptor component factor (houdc44)
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
US6255455B1 (en) 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
JP4215172B2 (ja) 1996-12-03 2009-01-28 アムジェン フレモント インク． 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
US6458547B1 (en) 1996-12-12 2002-10-01 Prolume, Ltd. Apparatus and method for detecting and identifying infectious agents
CA2196496A1 (fr) 1997-01-31 1998-07-31 Stephen William Watson Michnick Epreuve de complementation de fragments de proteines pour la detection d'interactions entre proteines
DE19732944A1 (de) 1997-07-31 1999-02-04 Thomae Gmbh Dr K Peptidische CGRP-Antagonisten
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
AU765703B2 (en) 1998-03-27 2003-09-25 Bruce J. Bryan Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
US6268474B1 (en) 1998-04-30 2001-07-31 Creighton University Peptide antagonists of CGRP-receptor superfamily and methods of use
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
EP1105427A2 (fr) 1998-08-17 2001-06-13 Abgenix, Inc. Production de molecules modifiees avec demi-vie serique prolongee
AU1936201A (en) * 1999-12-02 2001-06-12 Myriad Genetics, Inc. Protein-protein interactions
US20020090646A1 (en) 2000-05-03 2002-07-11 Amgen Inc. Calcitonin-related molecules
FR2821080B1 (fr) 2001-02-20 2003-12-19 Sanofi Synthelabo Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques
IL159177A0 (en) 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
WO2003027252A2 (fr) * 2001-09-27 2003-04-03 Merck & Co., Inc. Molecules d'adn isolees codant un recepteur humanise du peptide lie au gene de la calcitonine, animaux transgeniques non humains associes et methodes d'analyse
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
WO2004003140A2 (fr) * 2002-01-18 2004-01-08 Zymogenetics, Inc. Recepteurs multimeres des cytokines contenant zcytor17
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20040110170A1 (en) 2002-05-18 2004-06-10 The Regents Of The University Of California Cloning and characterization of calcitonin gene related peptide receptors
US20070071744A1 (en) * 2002-06-07 2007-03-29 Gotz Munch Agents which bind to epitopes of glycoprotein VI
DK1556020T3 (da) * 2002-08-12 2009-06-22 Birkir Sveinsson Anvendelse af CGRP-antagonistforbindelser til behandling af psoriasis
US20040176577A1 (en) * 2002-09-10 2004-09-09 Eva Rojer Immunoassays for specific determination of SCCA isoforms
WO2004097421A2 (fr) 2003-04-29 2004-11-11 Bayer Healthcare Ag Diagnostics et traitements destines a des maladies associees au recepteur de type recepteur calcitonine (calcrl)
CN1961000B (zh) 2004-02-11 2011-05-04 安米林药品公司 具有可选择特性的杂合多肽
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
PT1838733E (pt) 2004-12-21 2011-12-13 Medimmune Ltd Anticorpos direccionados a angiopoietina-2 e respectivos usos
WO2006134692A1 (fr) 2005-06-16 2006-12-21 Univ Shinshu Agent angiogénétique contenant de l’adrénoméduline comme principe actif
GB0521139D0 (en) 2005-10-18 2005-11-23 Univ Sheffield Therapeutic agent
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
SI3045182T1 (en) 2005-11-14 2018-08-31 Teva Pharmaceuticals International Gmbh An antibody to a peptide-associated peptide antagonist to calcitonin for treating a headache in aggregates
WO2007076336A1 (fr) * 2005-12-22 2007-07-05 Eli Lilly And Company Traitement de la migraine avec des anticorps anti-cgrp
AU2007348941B2 (en) * 2006-08-03 2011-08-04 Medimmune Limited Antibodies directed to alphaVbeta6 and uses thereof
GB0708002D0 (en) * 2007-04-25 2007-06-06 Univ Sheffield Antibodies
WO2009109908A1 (fr) 2008-03-04 2009-09-11 Pfizer Limited Procédés de traitement d'une douleur inflammatoire
FR2934597B1 (fr) * 2008-07-31 2013-04-19 Univ Aix Marseille Ii Anticorps se liant aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament.
JO3382B1 (ar) * 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
WO2011024113A1 (fr) 2009-08-28 2011-03-03 Rinat Neuroscience Corporation Procédés de traitement de la douleur viscérale par administration d'anticorps antagonistes dirigés contre le peptide associé au gène de la calcitonine
WO2013180295A1 (fr) 2012-06-01 2013-12-05 日本電信電話株式会社 Procédé de traitement de transfert de paquets et dispositif de traitement de transfert de paquets
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
AU2015318008B2 (en) 2014-09-15 2021-05-20 Amgen Inc. Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof
TWI799849B (zh) * 2015-04-24 2023-04-21 美商安美基公司 治療或預防偏頭痛之方法
US11385238B2 (en) 2017-06-30 2022-07-12 Amgen Inc. Methods of protein clips recovery
EA202092335A1 (ru) 2018-04-02 2021-01-22 Эмджен Инк. Композиции на основе эренумаба и пути их применения

Also Published As

Publication number Publication date
KR101740615B1 (ko) 2017-05-26
EP4585264A2 (fr) 2025-07-16
AU2013205271A1 (en) 2013-05-02
TW202241950A (zh) 2022-11-01
EP2379594A1 (fr) 2011-10-26
IL243784A0 (en) 2016-04-21
AU2009330175C1 (en) 2018-10-04
EA201891500A2 (ru) 2018-11-30
SMT201700504T1 (it) 2018-01-11
TWI754176B (zh) 2022-02-01
US9102731B2 (en) 2015-08-11
HRP20191341T8 (hr) 2020-02-07
US9862771B2 (en) 2018-01-09
CA2746858C (fr) 2017-10-03
JOP20190017A1 (ar) 2017-06-16
EP3184546B8 (fr) 2019-10-30
JP2014210815A (ja) 2014-11-13
KR20190054181A (ko) 2019-05-21
TW201032823A (en) 2010-09-16
NZ623541A (en) 2015-12-24
ME03601B (fr) 2020-07-20
CO6400232A2 (es) 2012-03-15
LTPA2018017I1 (lt) 2019-01-10
HRP20250807T8 (hr) 2026-02-27
HUS1800047I1 (hu) 2018-12-28
LUC00095I2 (fr) 2019-12-24
TW202026312A (zh) 2020-07-16
LTC2379594I2 (lt) 2020-04-10
AU2013205271C1 (en) 2018-10-04
CN102348722B (zh) 2016-06-08
EA201891500A3 (ru) 2019-03-29
AU2013205271B2 (en) 2016-07-14
JP2012513214A (ja) 2012-06-14
ES2746571T3 (es) 2020-03-06
TN2011000283A1 (en) 2012-12-17
CY2018032I2 (el) 2019-07-10
LT2379594T (lt) 2017-11-27
SI2379594T1 (sl) 2017-12-29
HRP20191341T1 (hr) 2019-10-18
US20250129172A1 (en) 2025-04-24
EP2379594B8 (fr) 2020-12-30
NZ606090A (en) 2014-08-29
SI3569620T1 (sl) 2025-08-29
US12134652B2 (en) 2024-11-05
CN106084045A (zh) 2016-11-09
CN102348722A (zh) 2012-02-08
KR20180043850A (ko) 2018-04-30
SG172307A1 (en) 2011-07-28
PL2379594T3 (pl) 2018-01-31
TWI574697B (zh) 2017-03-21
SI3184546T1 (sl) 2019-09-30
HRP20250807T1 (hr) 2025-09-12
ES3036151T3 (en) 2025-09-15
PT3184546T (pt) 2019-09-16
IL243784A (en) 2016-11-30
JP2019062907A (ja) 2019-04-25
US20210179723A1 (en) 2021-06-17
CN106084045B (zh) 2020-02-11
MX2011006804A (es) 2011-09-27
IL213429A (en) 2016-02-29
JO3382B1 (ar) 2019-03-13
BR122020010360B1 (pt) 2022-08-16
EA031320B1 (ru) 2018-12-28
UA108066C2 (uk) 2015-03-25
US20150376286A1 (en) 2015-12-31
CY2018032I1 (el) 2019-07-10
HRP20171690T1 (hr) 2017-12-15
DK3184546T3 (da) 2019-09-30
SG10201401879TA (en) 2014-06-27
TW201703796A (zh) 2017-02-01
RS56567B1 (sr) 2018-02-28
KR101853393B1 (ko) 2018-05-02
ZA201105418B (en) 2012-02-29
LT3569620T (lt) 2025-07-25
EP2379594B1 (fr) 2017-08-09
HUE034506T2 (en) 2018-02-28
CY1119465T1 (el) 2018-03-07
EA201100892A1 (ru) 2012-01-30
AR074857A1 (es) 2011-02-16
DK3569620T3 (da) 2025-08-04
CY1122658T1 (el) 2021-03-12
LUC00095I1 (fr) 2018-12-28
JOP20190017B1 (ar) 2023-03-28
IL213429A0 (en) 2011-07-31
JP6261132B2 (ja) 2018-01-17
KR20110106409A (ko) 2011-09-28
BRPI0922505A2 (pt) 2016-07-05
US20210179722A1 (en) 2021-06-17
CL2011001578A1 (es) 2012-01-20
KR20170061182A (ko) 2017-06-02
BRPI0922505B1 (pt) 2021-08-03
US20100172895A1 (en) 2010-07-08
RS59343B1 (sr) 2019-10-31
PE20120427A1 (es) 2012-05-13
ES2643835T3 (es) 2017-11-24
TWI688403B (zh) 2020-03-21
EP3184546B1 (fr) 2019-07-17
US12122841B2 (en) 2024-10-22
US20180142029A1 (en) 2018-05-24
JP7584577B2 (ja) 2024-11-15
AU2009330175A1 (en) 2011-06-23
CR20110400A (es) 2011-10-12
NO2379594T3 (fr) 2018-01-06
NL300961I2 (nl) 2019-01-15
EP3569620B1 (fr) 2025-05-07
LT3184546T (lt) 2019-09-10
PL3184546T3 (pl) 2019-12-31
NO2018042I1 (no) 2018-12-17
AU2009330175B2 (en) 2014-01-16
EP4585264A3 (fr) 2025-10-29
WO2010075238A1 (fr) 2010-07-01
PT2379594T (pt) 2017-11-16
JP2016026224A (ja) 2016-02-12
JP2021036912A (ja) 2021-03-11
PL3569620T3 (pl) 2025-10-20
EP3569620A1 (fr) 2019-11-20
FI3569620T3 (fi) 2025-07-15
PT3569620T (pt) 2025-07-21
EP3184546A1 (fr) 2017-06-28
JP2023116783A (ja) 2023-08-22
US20130071410A1 (en) 2013-03-21
JP5761805B2 (ja) 2015-08-12
HUE045966T2 (hu) 2020-01-28
HUE072123T2 (hu) 2025-10-28
CA2746858A1 (fr) 2010-07-01
DK2379594T3 (en) 2017-10-30
MY180564A (en) 2020-12-02
RS67071B1 (sr) 2025-08-29

Similar Documents

Publication Publication Date Title
MA32982B1 (fr) Proteines de liaison au recepteur cgrp humain
MA34004B1 (fr) Protéines de liaison à cd127
UA113609C2 (xx) Антигензв'язуючий білок, який зв'язує людський il-23
EA201000238A1 (ru) Антигенсвязывающие белки для il-18 рецептора и их применение
EA201391457A1 (ru) Белки, связывающиеся с bcma (cd269/tnfrsf17)
PH12013502205A1 (en) Antibodies to il-6 and their uses
EA201892184A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора
EA201001223A1 (ru) Стабилизированные белковые композиции
EA201290570A1 (ru) Конструкты, связывающиеся с ron, и способы их использования
EA201401107A1 (ru) Специфические антагонисты рецептора fgf-r4
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
CU24058B1 (es) Antagonistas de pcsk9
EA201790757A1 (ru) Связывающие антиген cd27l белки
TW200611911A (en) Antibodies to erythropoietin receptor and uses thereof
EA200901436A1 (ru) Антигенсвязывающие белки, связывающие par-2
EA201071126A1 (ru) Антагонисты рецепторов глюкагона
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
WO2011002968A3 (fr) Polypeptides et procédé de traitement
EA201291180A1 (ru) Композиции и способы применения терапевтических антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
NO20092743L (no) Antistoffer mot CD200R
DE602005027399D1 (de) Für humane matriptase spezifische bindungsproteine
EA201290630A1 (ru) Лечение расстройства обмена веществ
EA201000102A1 (ru) Антагонистические антитела к активируемому протеазой рецептору-1 (par1)